Telomir Pharmaceuticals Gains FDA Clearance for Telomir-Zn Phase 1/2 Trial in Triple-Negative Breast Cancer
Telomir Pharmaceuticals announced FDA IND clearance for Telomir-Zn to treat advanced triple-negative breast cancer, allowing a Phase 1/2 trial to proceed and marking a key step toward clinical development.
Telomir Pharmaceuticals (NASDAQ: TELO), a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application for Telomir-Zn to treat advanced or metastatic triple-negative breast cancer (TNBC). The clearance enables the company to initiate a first-in-human Phase 1/2 clinical trial designed to evaluate safety, dosing and preliminary antitumor activity, supported by preclinical pharmacology, toxicology and biomarker data as the company advances its lead candidate toward clinical development.
Triple-negative breast cancer is an aggressive subtype that lacks targeted therapies, making new treatment options critically important. Telomir-Zn, also referred to as Telomir-1, is a small-molecule therapeutic that targets fundamental epigenetic and metabolic mechanisms implicated in cancer, aging and degenerative disease. Preclinical studies have demonstrated activity involving modulation of intracellular metal homeostasis, redox balance, epigenetically regulated gene expression, mitochondrial function and genomic stability.
The FDA’s IND clearance represents a significant regulatory milestone for Telomir Pharmaceuticals, allowing the company to transition from preclinical to clinical development. The upcoming Phase 1/2 trial will provide initial data on the safety and tolerability of Telomir-Zn in patients with advanced TNBC, as well as early signals of efficacy. If successful, Telomir-Zn could address a substantial unmet medical need in a patient population with limited treatment options.
For more details on the announcement, the full press release is available at https://ibn.fm/p4e9J. Additional updates and information about Telomir Pharmaceuticals can be found in the company’s newsroom at https://ibn.fm/TELO.
The clearance comes at a time when the biotech industry is increasingly focused on novel mechanisms for hard-to-treat cancers. Telomir-Zn’s approach of targeting epigenetic and metabolic pathways sets it apart from conventional chemotherapies and immunotherapies, potentially offering a new avenue for patients who have progressed on standard treatments. The company’s preclinical data, which includes evidence of antitumor activity and a favorable safety profile, will be further validated in the clinical setting.
Telomir Pharmaceuticals is a preclinical-stage biotechnology company developing small-molecule therapeutics designed to target fundamental mechanisms in cancer, aging and degenerative disease. The lead program, Telomir-1 (Telomir-Zn), has shown promise in preclinical models. The IND clearance for TNBC marks a pivotal step in the company’s clinical development plan.